Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about IONS, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Donidalorsen FDA approved Aug 2025 · Dawnzera (Autoinjector) |
Hereditary Angioedema | Phase 3 · NCT05392114 | Active not recruiting |
| Zilganersen FDA approved Sep 2026 · Zanvastro |
Alexander Disease | Phase 3 · NCT04849741 | Active not recruiting |
| Olezarsen FDA approved Dec 2024 · Tryngolza (Autoinjector) |
Severe Hypertriglyceridemia | Phase 3 · NCT05681351 | Active not recruiting |
| Obudanersen | Angelman Syndrome | Phase 3 · NCT07782827 | Recruiting |
| ION363 | Amyotrophic Lateral Sclerosis | Phase 3 · NCT04768972 | Active not recruiting |
| Inotersen | Hereditary Transthyretin-Mediated Amyloid Polyneur | Phase 3 · NCT04136184 | Completed |
| ION337 | Dravet Syndrome | Phase 1/2 · NCT07531745 | Recruiting |
| ION440 | Methyl CpG Binding Protein 2 (MECP2) Duplication S | Phase 1/2 · NCT06430385 | Recruiting |
| ION582 | Angelman Syndrome | Phase 1/2 · NCT05127226 | Active not recruiting |
| ION717 | Prion Disease | Phase 1/2 · NCT06153966 | Active not recruiting |
| ION775 | Hypertriglyceridemia | Phase 2 · NCT07604974 | Recruiting |
| IONIS-AGT-LRx | Hypertension | Phase 2 · NCT04714320 | Completed |
| IONIS-FB-LRx | Macular Degeneration | Phase 2 · NCT03815825 | Completed |
| ION224 | Steatohepatitis, Nonalcoholic | Phase 2 · NCT04932512 | Completed |
| Sapablursen | Phlebotomy Dependent Polycythemia Vera | Phase 2 · NCT05143957 | Completed |
| ION356 | Pelizaeus-Merzbacher Disease | Phase 1 · NCT06150716 | Recruiting |
Also used in these trials (approved or third-party drugs, not IONS's own candidates): Tofersen, Eplontersen.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
IONS holds $2.7B in cash and short-term investments (as of Jun 30, 2026) and burns about $113.6M/quarter from operations, an estimated runway of 71.3 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 15 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when IONS files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| FMR, LLC | Institution (13F) | 24,631,956 | 14.82% | 2026-06-30 |
| Capital World Investors | Institution (13G, 5%+) | 21,186,369 | 12.75% | 2026-03-31 |
| Blackrock Inc. | Institution (13F) | 10,704,660 | 6.44% | 2026-06-30 |
| Vanguard Capital Management | Institution (13G, 5%+) | 8,344,732 | 5.02% | 2026-03-31 |
| Vanguard Portfolio Management LLC | Institution (13F) | 7,859,529 | 4.73% | 2026-06-30 |
| Wellington Management Group, LLP | Institution (13F) | 7,651,415 | 4.60% | 2026-06-30 |
| Two Sigma Investments, LP | Institution (13F) | 6,252,342 | 3.76% | 2026-06-30 |
| Royal Bank of Canada | Institution (13F) | 6,182,479 | 3.72% | 2026-06-30 |
| State Street Corporation | Institution (13F) | 4,334,848 | 2.61% | 2026-06-30 |
| T. Rowe Price Investment Management, Inc | Institution (13F) | 3,959,372 | 2.38% | 2026-06-30 |
| Brett P Monia Chief Executive Officer, Director · +1.05M options |
Insider | 242,760 | 0.15% | 2026-08-31 |
| Spencer R Berthelsen Director · +7,670 options |
Insider | 161,303 | 0.10% | 2026-07-15 |
Share count 166,184,322 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-06-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-08-31 filed 2026-09-02 |
O'NEIL PATRICK R. |
Other (J) | 63 | $51.31 | 59,205 |
| 2026-08-31 filed 2026-09-02 |
Monia Brett P |
Other (J) | 98 | $51.31 | 242,760 |
| 2026-08-31 filed 2026-09-02 |
BENNETT C FRANK |
Other (J) | 110 | $51.31 | 60,128 |
| 2026-08-31 filed 2026-09-02 |
Birchler Brian |
Other (J) | 58 | $51.31 | 102,883 |
| 2026-07-31 filed 2026-07-31 |
Hayden Michael R |
Purchase (P) | 5,000 | $51.60 | 24,000 |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
| Date | Drug | Type | Run-up 30d | Decision 1d | After 5d |
|---|---|---|---|---|---|
| 2026-09-22 | — | NDA | -23.6% | -2.2% | — |
| 2025-08-21 | — | NDA | +2.1% | +1% | -0.1% |
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for IONS and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →